FTC Injunction Temporarily Preserves Competition in Innovation of Specialized Heart Valve Devices
A federal judge has paused the merger of the only two companies developing a heart device made for high-risk patients suffering from aortic regurgitation, a potentially dangerous condition that occurs when the heart’s aortic valve doesn’t seal and allows blood to leak backward into the heart’s main pumping chamber. Eight million people have this condition in the U.S., which puts them at risk of heart failure, stroke, and severe breathing difficulties.
On Jan. 9, 2026, the U.S. District Court for the District of Columbia granted the Federal Trade Commission’s preliminary injunction stopping Edwards Lifesciences from acquiring JenaValve Technology. The injunction pauses the transaction while the FTC continues its administrative challenge.
The FTC states that the merger would eliminate competition in the development of transcatheter aortic valve replacement devices for aortic regurgitation (TAVR‑AR). No TAVR‑AR device is FDA‑approved, and the FTC argues that preserving competition during the development phase is essential for innovation, quality, and patient access.
FTC’s Rationale for Blocking the Merger
Edwards Lifesciences intended to acquire JenaValve for $945 million. Edwards had already acquired JC Medical in 2024, obtaining the J‑Valve AR program. The FTC asserts that combining JenaValve’s Trilogy system with JC Medical’s J‑Valve would consolidate the only two dedicated TAVR‑AR development pipelines in the United States.
The FTC’s complaint states:
- Edwards/JC Medical and JenaValve are the only firms conducting U.S. clinical trials for AR‑specific transcatheter valves.
- Trilogy and J‑Valve are designed to anchor in non‑calcified AR anatomy, unlike stenosis‑focused TAVR devices.
- Eliminating rivalry between these two programs would likely slow innovation, reduce quality improvements, and increase the risk that one program is abandoned under Edwards’ sole control.
The FTC further states that consolidation could raise future device prices if one firm controls all AR‑specific transcatheter technology entering the U.S. market.
FTC’s Market Definition
Product Market: TAVR‑AR Devices
The FTC defines the market as dedicated TAVR‑AR devices. The agency excludes:
- TAVR devices for aortic stenosis, which require heavy calcification for anchoring
- Surgical aortic valve replacement (SAVR), which is not a suitable alternative for many AR patients
- Off‑label use of stenosis devices in AR patients, which lacks consistent safety and performance
Geographic Market: United States
The FTC identifies the United States as the relevant market because:
- AR patients cannot rely on foreign devices that lack FDA approval
- U.S. reimbursement rules prevent international pricing from influencing domestic competition
Competition Between JenaValve and JC Medical
The FTC’s complaint describes ongoing competition between the firms, including:
- Device design and engineering improvements focused on anchoring stability and complication reduction
- Clinical performance improvements, including efforts to reduce pacemaker‑implantation rates
- Competition for clinical trial sites at major U.S. hospitals
- Recruitment of interventional cardiologists with AR specialization
- Race to complete pivotal trials and file premarket approval (PMA) applications
The FTC asserts that this competition is central to future patient outcomes because:
- No TAVR‑AR device is FDA‑approved
- AR patients currently depend on open‑heart surgery or off‑label TAVR use
- Competitive pressure determines the speed, quality, and scope of AR‑device development
Barriers to Entry in the TAVR‑AR Market
The FTC states that entry into the TAVR‑AR market is unlikely because:
- Class III cardiovascular devices require feasibility studies, pivotal trials, and PMA review
- Full development timelines typically exceed five years
- No other company is in U.S. clinical trials for a dedicated AR valve
- Stenosis‑focused TAVR devices cannot be repurposed for AR due to anatomical and anchoring differences
These barriers mean that eliminating JenaValve as an independent competitor would reduce the number of AR‑specific transcatheter developers from two to one.
Why the Court’s Merger Injunction Matters
The injunction preserves pipeline competition in a category where competition determines the future availability of minimally invasive AR treatments. The FTC emphasizes that more than 8 million Americans suffer from aortic regurgitation and that high‑risk patients have no FDA‑approved transcatheter option.
Maintaining two independent developers protects:
- The rate of innovation in AR‑specific technology
- The quality of device design, safety profiles, and complication‑reduction efforts
- Price competition once devices reach the commercial market
- Clinical choice for hospitals and interventional cardiologists
- Patient access, particularly in rural or disadvantaged regions where TAVR programs are already limited
While the case makes its way through the FTC’s administrative process, the ruling preserves the only active head‑to‑head competition capable of delivering the first FDA‑approved TAVR‑AR system to U.S. patients.
